Clinical and Biological Predictors of Durable Response to Idecabtagene Vicleucel in Relapsed/Refractory Multiple Myeloma (RRMM) (IMS 2026) - Sep 11, 2026 - Abstract #PA-086; Pres time: Sep 24, 2026; "Although idecabtagene vicleucel (ide-cel) is associated with lower response rates and shorter survival than ciltacabtagene autoleucel, a meaningful subset of patients achieves long-lasting responses. In this real-world multicenter cohort, ide-cel achieved durable disease control in 17% of heavily pre-treated RRMM patients. Durable response was independently predicted by three strata: functional status, cytogenetics, and systemic inflammation. Ferritin's independence from ECOG suggests a distinct inflammatory mechanism, consistent with observed association between inflammation and impaired CAR-T efficacy."
Clinical • CNS Disorders • Hematological Malignancies • Inflammation • Movement Disorders • Multiple Myeloma • Parkinson's Disease
|
|
Gliceida M. Galarza Fortuna1; Lekha Mikkilineni2; Rachid Baz3; Omar Castaneda Puglianini3; Melissa Alsina3; Frederick Locke3; Mahmoud M. Gaballa4; Krina Patel4; Oren Pasvolsky4; Surbhi Sidana5; Yizhe Xu6; Yuxin Zhao1; Christopher Cahoon1; Noa Biran7; Leyla Shune8; Jack Khouri9; James A. Davis10; Larry Anderson11; Peter Voorhees12; Danai Dima13; Sneha Purvey14; Hamza Hassan15; Amandeep Godara16; Doris Hansen3; Douglas W. Sborov16
|